# Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).

> **NCT07684560** · PHASE1 · NOT_YET_RECRUITING · sponsor: **AlphaMol Science Ltd. (Shanghai)** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria (CSU)
- Healthy Volunteers

## Interventions

- **DRUG:** Alpha-0261
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07684560
- **Lead sponsor:** AlphaMol Science Ltd. (Shanghai)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684560, "Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*